Dlin-MC3-DMA: Ionizable Cationic Liposome for Potent siRNA & mRNA Delivery

Executive Summary: Dlin-MC3-DMA (DLin-MC3-DMA, CAS No. 1224606-06-7), offered by APExBIO, is a validated ionizable cationic liposome that underpins state-of-the-art lipid nanoparticle siRNA delivery and mRNA drug delivery workflows (Wang et al., 2022). Its unique pH-dependent charge enables efficient endosomal escape and cytoplasmic delivery of nucleic acids, with in vivo silencing potency up to 1000-fold higher than its predecessor DLin-DMA (APExBIO product page). Dlin-MC3-DMA is integral to LNP formulations used in FDA-approved mRNA vaccines and is supported by robust, peer-reviewed benchmarks. Its workflow compatibility, storage parameters, and solubility profile are defined by precise, reproducible conditions, making it a gold standard for hepatic gene silencing and cancer immunochemotherapy research.

Biological Rationale

Dlin-MC3-DMA is an ionizable cationic lipid essential for assembling lipid nanoparticles (LNPs) that deliver siRNA and mRNA payloads into mammalian cells. The LNP platform is foundational to modern nucleic acid therapeutics, including mRNA vaccines (e.g., BNT162b2, mRNA-1273) (Wang et al., 2022). Ionizable lipids like Dlin-MC3-DMA facilitate nucleic acid encapsulation, protect against serum nucleases, and promote intracellular delivery. Unlike permanently charged cationic lipids, Dlin-MC3-DMA is protonated only at acidic pH, minimizing off-target toxicity at physiological pH (7.4). The ability to efficiently silence hepatic genes, such as Factor VII and TTR, underlines its role in gene therapy and rare disease treatment. LNPs containing Dlin-MC3-DMA are also platforms for immunomodulation and cancer immunochemotherapy, supporting both preclinical and translational research pipelines.

Mechanism of Action of Dlin-MC3-DMA (DLin-MC3-DMA, CAS No. 1224606-06-7)

Dlin-MC3-DMA is a synthetic lipid with a tertiary amine that is neutral at physiological pH but becomes positively charged in acidic environments, such as the endosome. This property enables several mechanistic steps:

• Encapsulation: During formulation, Dlin-MC3-DMA interacts with anionic nucleic acids (siRNA or mRNA), resulting in efficient encapsulation within LNPs.
• Cellular Uptake: LNPs are taken up by cells via endocytosis.
• Endosomal Escape: Acidification in endosomes protonates Dlin-MC3-DMA, increasing its positive charge and destabilizing the endosomal membrane. This promotes release of the nucleic acid cargo into the cytoplasm (Fig. 6, Wang et al., 2022).
• Gene Silencing/Expression: Released siRNA engages the RNA-induced silencing complex (RISC), while mRNA is translated by ribosomes.

At neutral pH, Dlin-MC3-DMA remains uncharged, which reduces non-specific interactions and systemic toxicity (see contrast: this article provides deeper mechanistic context than prior summaries).

Evidence & Benchmarks

• Dlin-MC3-DMA LNPs achieve siRNA-mediated hepatic gene silencing with approximately 1000-fold greater potency than DLin-DMA in mice (ED50 = 0.005 mg/kg) (Wang et al., 2022, Table 1).
• In non-human primates, Dlin-MC3-DMA LNPs silence transthyretin (TTR) gene with an ED50 of 0.03 mg/kg (Wang et al., 2022, Table S3).
• LightGBM-based machine learning models identify Dlin-MC3-DMA as the optimal ionizable lipid for mRNA vaccine LNPs, outperforming SM-102 in in vivo IgG titer induction in mice (Wang et al., 2022, Fig. 3).
• LNPs formulated with Dlin-MC3-DMA, DSPC, cholesterol, and PEG-DMG show high stability and efficacy in both siRNA and mRNA delivery protocols (APExBIO product page).
• Solubility in ethanol is ≥152.6 mg/mL; Dlin-MC3-DMA is insoluble in water and DMSO (APExBIO product page).
• Products should be stored at -20°C or below to prevent degradation; prompt use of solutions is recommended (this article details storage pitfalls and optimization).

Applications, Limits & Misconceptions

Dlin-MC3-DMA is suitable for:

• Lipid nanoparticle siRNA delivery for hepatic gene silencing
• mRNA vaccine formulation and immunomodulatory applications
• Cancer immunochemotherapy and translational research

It is widely adopted in both preclinical and clinical research, with FDA-approved mRNA vaccines using related LNP platforms (Wang et al., 2022).

Common Pitfalls or Misconceptions

• Dlin-MC3-DMA is not water-soluble; improper solvent selection impedes formulation efficiency.
• It is not suitable for direct DNA delivery; optimized for RNA (siRNA, mRNA), not for plasmid or genomic DNA.
• Neutral at physiological pH; does not facilitate endosomal escape unless exposed to acidic conditions.
• Degradation risk at room temperature; improper storage increases hydrolysis and loss of efficacy.
• Not universally optimal for all tissues; LNPs with Dlin-MC3-DMA show best results in hepatic targeting via intravenous injection, less so for non-liver tissues.

For troubleshooting and advanced technical workflows, see this scenario-driven guide, which this article extends with new machine-learning benchmarks and actionable integration tips.

Workflow Integration & Parameters

To formulate LNPs with Dlin-MC3-DMA:

• Mix Dlin-MC3-DMA, DSPC, cholesterol, and PEG-DMG in ethanol at defined molar ratios (typical: 50:10:38.5:1.5).
• Rapidly combine with aqueous nucleic acid solution (siRNA or mRNA) under acidic buffer (pH 4.0–4.5) for encapsulation.
• Dialyze or buffer-exchange to physiological pH (7.4) prior to in vivo use, ensuring Dlin-MC3-DMA is neutralized to minimize toxicity.
• Store bulk lipid at -20°C or below; use freshly prepared solutions to avoid degradation.
• Target N/P (amine:phosphate) ratio for optimal efficacy is typically 6:1 (Wang et al., 2022).

For further mechanistic and troubleshooting insights, see this immunomodulatory delivery analysis; this article updates the field with recent machine-learning-driven evidence and storage guidance.

Conclusion & Outlook

Dlin-MC3-DMA is a cornerstone of lipid nanoparticle-mediated gene silencing and mRNA vaccine formulation. Its unique ionizable profile, high in vivo potency, and machine-learning-validated superiority over other lipids make it the gold standard for hepatic gene silencing and immunotherapy. As machine learning and rational design drive further LNP optimization, Dlin-MC3-DMA will remain central to next-generation nucleic acid therapeutic platforms. For detailed specifications and purchasing, visit the APExBIO Dlin-MC3-DMA (DLin-MC3-DMA, CAS No. 1224606-06-7) product page.